IFAM
PTGX icon

Institutional & Family Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Institutional & Family Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$554 Hold
16
– – ﹤0.01% 698
2024
Q1 		$463 Buy
+16
New +$435 ﹤0.01% 697

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Institutional & Family Asset Management's PTGX Position: Q2 2024 in Review

Institutional & Family Asset Management held its Protagonist Therapeutics (PTGX) position steady in Q2 2024 at 16 shares worth $554. The position accounts for ﹤0.01% of the portfolio, ranked #698.

Institutional & Family Asset Management first reported a position in PTGX in Q1 2024 and has held it in 2 quarters since. 188 funds tracked by Wall St. Rank hold PTGX as of Q2 2024.

  • Institutional & Family Asset Management held 16 shares of Protagonist Therapeutics worth $554 as of Q2 2024.
  • Institutional & Family Asset Management left its Protagonist Therapeutics share count unchanged in Q2 2024.
  • Protagonist Therapeutics made up ﹤0.01% of Institutional & Family Asset Management's portfolio in Q2 2024, its #698 holding.
  • Institutional & Family Asset Management first reported a position in Protagonist Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 188 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2024.

Based on Institutional & Family Asset Management's 13F filing for Q2 2024, filed 5 Jul 2024.